A Phase 0 Pharmacokinetic, Pharmacodynamic Study of ABT-888, an Inhibitor of Poly (ADP-Ribose) Polymerase (PARP), in Refractory Solid Tumors and Lymphoid Malignancies.

Trial Profile

A Phase 0 Pharmacokinetic, Pharmacodynamic Study of ABT-888, an Inhibitor of Poly (ADP-Ribose) Polymerase (PARP), in Refractory Solid Tumors and Lymphoid Malignancies.

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Mar 2012

At a glance

  • Drugs Veliparib (Primary)
  • Indications Chronic lymphocytic leukaemia; Follicular lymphoma; Solid tumours
  • Focus Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 14 Mar 2012 Additional lead trial centre identified as reported by ClinicalTrials.gov.
    • 14 Mar 2012 Actual end date changed from Jun 2008 to Apr 2009 as reported by ClinicalTrials.gov.
    • 19 Jun 2008 Status change from in progress to completed, according to clinicaltrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top